Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
HS-243
Cat. No.:
0225LY-1275
Appearance:
Solid
Purity:
≥97%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
HS-243 exhibits anti-inflammatory and anticancer properties by inhibiting IRAK-1 and IRAK-4 with IC50 values of 24 nM and 20 nM, respectively.
Synonym:
848249-10-5; 3-Nitro-N-(1-propyl-1H-benzo[d]imidazol-2-yl)benzamide; 3-nitro-N-(1-propyl-1,3-benzodiazol-2-yl)benzamide; Z29077789; 3-Nitro-N-(1-propyl-1H-benzo[d]imidazol-2(3H)-ylidene)benzamide
CAS No.:
848249-10-5
Compound CID:
4800865
Formula:
C17H16N4O3
Formula Weight:
324.33
Specification
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
HS-243 can be used in oncology research to study the potent inhibition of the CDK9 signaling pathway.
Library Information
Target:
MAPK; IRAK; CDK
Receptor:
IRAK-4; IRAK-1; TAK1; CLK4
Pathways:
Immunology/Inflammation; Cell cycle/Checkpoint; NF-κB; MAPK
Plate Number:
AOCL-17
Plate Location:
d2
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
10 mg/mL; 30.83 mM
